These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17691933)

  • 1. Nanochemistry-based immunotherapy for HIV-1.
    Lori F; Calarota SA; Lisziewicz J
    Curr Med Chem; 2007; 14(18):1911-9. PubMed ID: 17691933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DermaVir, a novel HIV immunisation technology.
    Lori F; Trocio J; Bakare N; Kelly LM; Lisziewicz J
    Vaccine; 2005 Mar; 23(17-18):2030-4. PubMed ID: 15755566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of topical DNA vaccines adjuvanted by cytokines.
    Lisziewicz J; Calarota SA; Lori F
    Expert Opin Biol Ther; 2007 Oct; 7(10):1563-74. PubMed ID: 17916048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals.
    Lisziewicz J; Bakare N; Calarota SA; Bánhegyi D; Szlávik J; Ujhelyi E; Tőke ER; Molnár L; Lisziewicz Z; Autran B; Lori F
    PLoS One; 2012; 7(5):e35416. PubMed ID: 22590502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DermaVir: a novel topical vaccine for HIV/AIDS.
    Lisziewicz J; Trocio J; Whitman L; Varga G; Xu J; Bakare N; Erbacher P; Fox C; Woodward R; Markham P; Arya S; Behr JP; Lori F
    J Invest Dermatol; 2005 Jan; 124(1):160-9. PubMed ID: 15654970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of viral rebound through therapeutic immunization with DermaVir.
    Lisziewicz J; Trocio J; Xu J; Whitman L; Ryder A; Bakare N; Lewis MG; Wagner W; Pistorio A; Arya S; Lori F
    AIDS; 2005 Jan; 19(1):35-43. PubMed ID: 15627031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical DermaVir vaccine targeting dendritic cells.
    Lisziewicz J; Kelly L; Lori F
    Curr Drug Deliv; 2006 Jan; 3(1):83-8. PubMed ID: 16472097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.
    Lori F
    Expert Rev Vaccines; 2011 Oct; 10(10):1371-84. PubMed ID: 21988301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
    Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
    Calarota SA; Weiner DB; Lori F; Lisziewicz J
    Vaccine; 2007 Apr; 25(16):3070-4. PubMed ID: 17292518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.
    Calarota SA; Dai A; Trocio JN; Weiner DB; Lori F; Lisziewicz J
    Vaccine; 2008 Sep; 26(40):5188-95. PubMed ID: 18462844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.
    Rodriguez B; Asmuth DM; Matining RM; Spritzler J; Jacobson JM; Mailliard RB; Li XD; Martinez AI; Tenorio AR; Lori F; Lisziewicz J; Yesmin S; Rinaldo CR; Pollard RB
    J Acquir Immune Defic Syndr; 2013 Dec; 64(4):351-9. PubMed ID: 24169120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-specific immunity during structured antiviral drug treatment interruption.
    Moss RB; Brandt C; Giermakowska WK; Savary JR; Theofan G; Zanetti M; Carlo DJ; Wallace MR
    Vaccine; 2003 Mar; 21(11-12):1066-71. PubMed ID: 12559781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Based Immunoengineered Approaches for Combating HIV.
    Bowen A; Sweeney EE; Fernandes R
    Front Immunol; 2020; 11():789. PubMed ID: 32425949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
    Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
    J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1.
    Walsh SR; Bhardwaj N; Gandhil RT
    Curr HIV Res; 2003 Apr; 1(2):205-16. PubMed ID: 15043203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune reconstitution in HIV-1-infected patients.
    Imami N; Hardy G; Pires A; Burton C; Pido-Lopez J; Mela C; Gotch F
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1138-45. PubMed ID: 12211404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.